

Professor T J Powles CBE, Phd FRCP

## BIBLIOGRAPHY

1967 – PRESENT

## Books

Prostaglandins and Cancer. Eds. T.J. Powles, R.S. Bockman, K.V. Honn, P. Ramwell. Publishers, Alan Liss Inc., New York, 1982.

Breast Cancer Management. Eds. R.C. Coombes, T.J. Powles, H.T. Ford, J.C. Gazet. Publishers, Academic Press Inc. (London) Ltd.1981.

Bone Metastases: new perspectives in the management of advanced breast cancer. Ed T J Powles. Publishers Mediq Ltd, London. 1991

Medical management of breast cancer. Eds TJ Powles, IE Smith. Publishers Martin Dunitz, London 1991.

Breast cancer: Sharing the decision. Eds. AM Maslin, TJ Powles. Publishers Oxford University Press, England 1999.

## Papers, Chapters, Letters

- 1 Powles TJ, Easty GC, Easty DM, Bondy, PK, Neville A.M.  
Aspirin inhibition of in vitro osteolysis stimulated by  
Parathyroid hormone and PGE  
Nature 245:83 1973
- 2 Powles TJ, Clarke M, Easty DM, Easty GC, and Neville AM  
Inhibition by aspirin and indomethacin of osteolytic tumour deposits and  
hypercalcaemia in rats with Walker tumour and its possible application to human breast  
cancer. Br J Cancer 28: 316-321 (1973)
- 3 Powles TJ, Easty GC, Easty DM, Neville AM (letter)  
Antimetastatic effect of aspirin Lancet I, 100 (1973)
- 4 Powles TJ, Easty DM, Easty GC, Neville AM (letter)  
Tumour induced osteolysis Lancet II, 504 (1973)
- 5 Powles TJ, Easty DM, Easty GC, Neville AM (letter)  
Tumour induced osteolysis  
New Eng J Med 291, 105 (1974)
- 6 Bondy PK, and Powles TJ  
Antiemetics, prolactin and breast cancer (letter)  
Br Med J 4, 228, (1974)
- 7 Powles TJ, Leese CL, and Bondy PK  
Hydroxyproline excretion in patients with breast cancer and response to treatment  
Br Med J I, 164-166 (1975)
- 8 Smith IE, and Powles TJ (letter)

Mithramycin for hypercalcaemia associated with myeloma and other malignancies  
Br Med J 1: 268 (1975)

- 9 Powles TJ, Easty GC, Easty DM, Dowsett M and Neville AM  
Some Studies on the Anti-Metastatic Effect of Aspirin.  
IN Proceedings of Aspirin Symposium (1975) pp 31-33. Pub. Rayleigh Printers, Essex  
Ed Dale TLC
- 10 Powles TJ, Dowsett M, Easty DM, Easty GC, Neville AM  
Breast cancer osteolysis, bone metastases and anti-osteolytic effect of aspirin  
Lancet 1, 608-610 (1976)
- 11 Dowsett M, Easty GC, Powles TJ, Easty DM, and Neville AM  
Human breast tumour induced osteolysis and prostaglandins.  
Prostaglandins 11, 447-460 (1976)
- 12 Dowsett M, Eastman AR, Easty DM, Easty GC, Powles TJ and Neville AM  
Prostaglandin mediation of collagenase-induced bone resorption  
Nature 263, 72-74 (1976)
- 13 Dowsett M, Gazet J-C, Powles TJ, Easty GC, and Neville AM  
Benign breast lesions and osteolysis  
Lancet 1, 970-971 (1976)
- 14 Powles TJ, Rosset G, Leese CL, and Bondy PK  
Early morning hydroxyproline excretion in patients with breast cancer  
Cancer 38, 2564-2566 (1976)
- 15 Easty GC, Powles TJ, Easty DM, Dowsett M, and Neville AM  
The detection of osteolytic substances produced by human breast tumours  
IN Organ Culture in Biomedical Research. Ed. Balls and Monnickendam., Pubs.  
Cambridge University Press p.367-377 (1976)
- 16 Smith IE, Taylor KJW, McCready VR, Powles, TJ, and Bondy PK  
A comparison of grey-scale ultrasound with other methods for the detection of liver  
metastases from breast carcinoma  
Clinical Oncology, 2, 47-53 (1976)
- 17 Coombes RC, Neville AM, Bondy PK, and Powles TJ  
Failure of Indomethacin to reduce hydroxyproline excretion of hypercalcemia in patients  
with breast cancer  
Prostaglandins 12, 1027-1035 (1976)
- 18 Powles TJ  
Factors influencing metastasis in bone  
IN Secondary Spread in Breast Cancer p81-93. Heinemann Publishers, Ed. Basil A. Stoll  
(1977)

- 19 Powles TJ  
Mechanisms for the development of bone metastases and hypercalcaemia in patients with breast cancer  
Proc Roy Soc Med 70, 199-201 (1977)
- 20 Cornbleet M, Bondy PK, and Powles TJ  
Fatal irreversible hypercalcaemia in breast cancer  
Br Med J 1, 145 (1977)
- 21 Dady PJ, Gazet J-C, Ford HT, and Powles TJ  
Combination chemotherapy for thrombocytopenia with bone marrow metastases from breast cancer  
Br Med J 1, 554-555 (1977)
- 22 Coombes RC, Powles TJ, Gazet J-C, Ford HT, Nash AG, Sloane JP, Thomas P, Keyser JW, Marcus D, Stimson W, Neville AM  
A biochemical approach to the staging of human breast cancer  
Cancer, 40, 937-944 (1977)
- 23 Easty GC, Dowsett M, Powles TJ, Easty GC, Gazet J-C, Neville AM  
Hypercalcaemia in malignant disease.  
Proc Roy Soc Med, 70, 191-195 (1977)
- 24 Coombes RC, Powles TJ, Joplin GP  
Calcium metabolism in breast cancer.  
Proc Roy Soc Med 70, 195-199 (1977)
- 25 Powles TJ, Coombes RC, Neville AM, Ford HT, Gazet J-C, Levine L  
15-keto-13, 14-dihydroprostaglandin E<sub>2</sub> concentrations in serum of patients with breast cancer Lancet 11, 138, (1977)
- 26 Russell JA, Baker JW, Dady PJ, Ford HT, Gazet J-C, McKinna JA, Nash AG, Powles TJ  
Response of metastatic breast cancer to combination chemotherapy according to site  
Br Med J 11: 1390-1391 (1977)
- 27 Powles TJ  
Prostaglandins and Breast Cancer  
IN Tumour Markers, ed. K Griffiths, AM Neville and CG Pierrepoint, p.291-297 (1977)  
Pub Alphas Omega Publishing Company Limited, Cardiff
- 28 Coombes RC, Neville AM, and Powles TJ  
The effects of calcitonin, mithramycin and indomethacin in breast cancer.  
IN Bone Disease and Calcitonin. Ed. John A. Kains, Pub. Armour Company Limited, p.103-110 (1977)

- 29 Powles TJ, Easty GC, Easty DM, Dowsett M, and Neville AM Factors influencing development of bone metastases.  
IN *Cancer Invasion and Metastases: Biologic Mechanisms and Therapy* Ed. S.B. Davy, Raven Press, N.Y. pp.425-429 (1977)
- 30 Coombes RC, Powles TJ, Gazet JC, Ford HT, Sloane JP, Laurence DJR, Neville AM  
*Biochemical Markers in Human Breast Cancer*  
*Lancet* 1, 132-134 (1977)
- 31 Coombes RC, Powles TJ, Neville AM  
Evaluation of biochemical markers in breast cancer  
*Proc Roy Soc Med* 70, 843-845 (1977)
- 32 Powles TJ  
Chemotherapy in breast cancer  
*South West Regional Cancer Reports* 3, 9-12 (1978)
- 33 Gazet J-C, Ford HT, Powles TJ  
Surgical management of breast cancer  
IN *Carcinoma of the Breast*, Ed. Joslin CA MCS Publications, p.7-13 (1978)
- 34 Smith IE, Powles TJ  
Multimodal therapy for Stage II breast cancer (letter)  
*Lancet*, 1, 1313 (1978)
- 35 Powles TJ  
Endocrine therapy  
IN *Oncology for Nurses and Health Care Professionals*. Ed. R. Tiffany, Publishers, George Allan & Unwin, (1978)
- 36 Smith IE, McKinna JA, Nash AG, Neville AM, Gazet J-C, Ford HT, and Powles TJ  
Aminoglutethimide in treatment of metastatic breast carcinoma.  
*Lancet* 11, 646-649 (1978)
- 37 Russell JA, Baker JW, Dady PJ, Ford HT, Gazet J-C, McKinna JA, Nash AG, and Powles TJ  
Combination chemotherapy of metastatic breast cancer with Vincristine, Adriamycin and Prednisolone  
*Cancer* 41, 396-399 (1978)
- 38 Meirion Thomas J, Fitzharris BM, Redding WH, Williams JE, Trott PA, Powles TJ, Ford HT, Gazet J-C  
Clinical examination, xeromammography and fine needle aspiration cytology in diagnosis of breast tumours  
*Br Med J* 2, 1139-1141 (1978)
- 39 Meirion Thomas J, Redding WH, Coombes RC, Sloane JP, Ford HT, Gazet J-C, Powles TJ

Failure to detect intra-abdominal metastases from breast cancer: a case for staging laparotomy *Br Med J* 11, 157-159 (1978)

- 40 Smith IE, Hedley DW, Powles TJ, McElwain TJ  
Vindesine: A phase II study in the treatment of breast cancer, malignant melanoma and other tumours  
*Cancer Treatment Reports* 62, 1427-1433 (1978)
- 41 Powles TJ, Ford HT, Gazet J-C  
Chemotherapy in advanced disease  
*IN Carcinoma of the Breast*. Ed. CA Joslin MCS Publications, p.41-46, (1978)
- 42 Powles TJ, Alexander P, Millar JL  
Enhancement of anti-cancer activity of cytotoxic chemotherapy with protection of normal tissues by inhibition of PG synthesis.  
*Journal of Biochem Pharmacol* 27, 1389-1392 (1978)
- 43 Smith IE, Powles TJ  
Aminoglutethimide in breast cancer  
*Lancet (Letter)* 2, 1149 (1978)
- 44 Redding WH, Thomas JM, Powles TJ, Ford HT, Gazet J-C  
Age and prognosis in breast cancer  
*Br Med J*, 1, 1465 (1979)
- 45 Van Oosterom AT, Powles TJ, Hamersma E, Smith IE and Engelsman E  
A Phase II study of Mitomycin C in refractory advanced breast cancer. A multi centre pilot study IN Breast Cancer - Experimental and Clinical Aspects. Proc. 2nd EORTC Breast Cancer Conference, Copenhagen, 1979. Ed ET Mouridsen & T Palshof, Copenhagen, Pubs. Pergamon Press pp 275-277 (1979)
- 46 Coombes RC, Neville AM, Gazet J-C, Ford HT, Nash AG, Baker JW, Powles TJ  
Agents affecting osteolysis in patients with breast cancer  
*Cancer Chemo & Pharmacol* 111, 41-44, (1979)
- 47 Smith IE, Ford HT, Gazet JC, Powles TJ  
Premarin in the management of metastatic breast carcinoma in post menopausal patients  
*Clinical Oncology* 5, 159-162 (1979)
- 48 Smith IE, and Powles TJ  
Vindesine in the treatment of breast cancer  
*Cancer Chemotherapy and Pharmacol*, 2, 261-262 (1979)
- 49 Coombes RC, Powles TJ, Gehrke CW, Waalkes TP, Neville AM Nucleoside excretion in breast cancer: Comparison with other biochemical tumour-index substances  
*Investigative and Cell Pathology* 2, 11-14 (1979)

- 50 Powles TJ  
Prostaglandins and Cancer  
Cancer Topics 11,6-7 (1979)
- 51 Powles TJ  
Anti-inflammatory drugs and tumour growth  
Lancet (1979); i: 420-21
- 52 Powles TJ  
Prostaglandins and Human Breast Cancer  
Prostaglandins and Therapeutics, 5, 1-8 (1979)
- 53 Powles TJ and Millar J  
Non-steroidal anti-inflammatory drugs and cytotoxics  
Cancer Treatment Reviews (Suppl) 6, 63- 67 (1979)
- 54 Powles TJ and Millar J  
Interactions des substances antimitotiques et anti-inflammatoires dans les tissus normaux et neoplasiques  
IN Colloque Europeen sur le mode d'action des anti-inflammatoires non-steroidiens p.109-110 (1979). Pubs. Lab. Boot Dacour. Ed. S.S. Adams et al.
- 55 Powles TJ  
Prostaglandines et Osteolyse  
IN Colloque Europeen sur le mode d'action des anti-inflammatoires non steroidiens p95-96 (1979) Pubs. Lab Boot Dacour. Ed. S.S. Adams et al
- 56 Smith IE, Hedley DW, Powles TJ, McElwain TJ  
Clinical experience with Vindesine in 60 patients with solid tumours  
IN Vindesine Ed RN Wild, Publishers Creative Packaging, Eli Lilly & Co Ltd Basingstoke pp11-16 (1979)
- 57 Coombes RC, Dady PJ, Parsons C, Powles TJ  
Mithramycin Therapy: An adjunct to conventional treatment of hypercalcaemia and bone metastases in breast cancer.  
Metab. Bone Dis and Rel Res. 2, 199-202 (1980)
- 58 Smith IE, Hedley DW, Coombes RC, Powles TJ  
A comparison of combination chemotherapy using vindesine or vincristine with adriamycin in the treatment of advanced breast carcinoma  
Cancer Treatment Reviews 7 71-73 (1980)
- 59 Powles TJ, Coombes RC, Smith IE, Jones JM, Ford HT, Gazet J-C Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer  
Lancet 1,580-582 (1980)

- 60 Bailey MJ, Royce C, Sloane JP, Ford HT, Powles TJ, Gazet J-C Bilateral carcinoma of the breast. *Br J Surg* 67, 514-516 (1980)
- 61 Dady PJ, Coombes RC, Smith IE, Parsons CA, Ford HT, Gazet J-C, Henk JM, Nash AG and Powles TJ  
Use of an anti-osteolytic agent in treatment of patients with bone metastases from breast cancer.  
IN *Breast Cancer - Experimental and Clinical Aspects*. Eds HT Mouridsen and T Palshof Pergamon Press pp.131-135 (1980)
- 62 Smith IE, Coombes RC, Ford HT, Gazet J-C, Harmer C, Jones M, McKinna JA and Powles TJ Aminoglutethimide in the management of advanced breast cancer  
IN *Breast Cancer - Experimental and Clinical Aspects* Eds HT Mouridsen and T.Palshof Pergamon Press, pp.99-101 (1980)
- 63 Smith IE, Coombes RC, Evans BD, Ford HT, Gazet J-C, Gordon C, McKinna JA, and Powles TJ Vindesine as a single agent and in combination with adriamycin in the treatment of metastatic breast carcinoma.  
IN *Breast Cancer - Experimental and Clinical Aspects*. Eds. Mouridsen and Palshof. Pergamon Press. pp.271-273 (1980)
- 64 Coombes RC, Powles TJ, Ford HT, Gazet J-C, Gherke CW, Keyser JW, Mitchell PEG, Patel S, Stimson WH, Tsou KC, Worwood M, Neville AM  
The value of sequential marker estimations following mastectomy for breast cancer.  
IN *Breast Cancer - Experimental and clinical aspects*. Eds. Mouridsen and Palshof. Pergamon Press Ltd., Oxford pp.25-30 (1980)
- 65 Powles TJ, Dady PJ, Williams J, Easty GC, Coombes RC  
Use of inhibitors of prostaglandin synthesis in patients with breast cancer  
*Advances in Prostaglandin and Thromboxane Research*, 6, 511-516 (1980)
- 66 Powles TJ, Frank G, Millar JL  
Interactions of cytotoxic and anti-inflammatory agents on normal and neoplastic tissue.  
*Advances in Prostaglandin and Thromboxane Research*, 6, 587-589 (1980)
- 67 Coombes RC, Dearnaley D, Humphreys J, Gazet J-C, Ford HT, Nash AG, Mashiter K and Powles TJ  
Danazol treatment of advanced breast cancer  
*Cancer Treatment Reports* 64, 1073-1076 (1980)
- 68 Powles TJ  
Prostaglandins and metastases  
IN *Metastatic Tumour Growth* Ed E Grundmann Publishers Gustav Fischer Verlag, Stuttgart, New York pp 245-247 (1980)
- 69 Powles TJ  
PG Synthetase Inhibitors in patients with cancer

- IN Prostaglandin Synthetase Inhibitors: New Clinical Applications Publishers Alan R Liss, Inc, New York pp 183-186 (1980)
- 70 Powles TJ, Gazet JC, Ford HT, Milan J, Dady PJ and Coombes RC Early detection and monitoring of secondary bone tumours  
IN Bone and Tumours Symposium CEMO III, Basel, November 1979 Eds A Donath and B Courvoisier Publishers L'Imprimerie Medecine et Hygiene, Geneve, pp105-108 (1980)
- 71 Coombes RC, Powles TJ, Gazet JC, Ford HT, McKinna A, Nash AG, Neville AM  
Assessment of biochemical tests to screen for metastases in patients with breast cancer  
Lancet 1, 296-298 (1980)
- 72 Coombes RC, Powles TJ, Abbott M, De Rivas L, Ford HT, McCready VR, Neville AM, Gazet J-C  
Physical tests for distant metastases in patients with breast cancer  
Proc Roy Soc Med. 73, 617-623 (1980)
- 73 Grudzinskas JG, Coombes RC, Ratcliffe JG, Gordon YB, Powles TJ, Neville AM and Chard T  
Circulating levels of pregnancy specific B<sub>1</sub> glycoprotein in patients with testicular, bronchogenic and breast carcinomas  
Cancer 45, 102-103 (1980)
- 74 Powles TJ  
Chemotherapy and Survival in Breast Cancer (Letter)  
Lancet 1, 984 (1980)
- 75 de Rivas L, Coombes RC, McCready VR, Gazet JC, Ford HT, Neville AM, Powles TJ.  
Tests for liver metastases in breast cancer: evaluation of liver scan and liver ultrasound.  
Clinical Oncology 6, 225-230 (1980)
- 76 Coombes RC, Abbott M, Dearnaley DP, Moshakis V, Powles TJ, Neville AM  
Carcinoembryonic antigen estimations as an aid to the management of breast cancer.  
IN Proceedings CEA Und Andere Tumormarker, Ein Symposiumsband, 1980 - Tumor Diagnostic, Verlag, pp 148 - 160.
- 77 Coombes RC, Jarman M, Harland S, Ratcliffe WA, Powles TJ, Taylor GN, O'Hare M, Nice E, Foster AB and Neville AM  
Aminoglutethimide: metabolism and effects on steroid synthesis in vivo.  
J Endocrinol 87, 31 (1980)
- 78 Dearnaley DP, Patel S, Powles T and Coombes RC  
Carcinoembryonic antigen estimation in cerebrospinal fluid in patients with metastatic breast cancer  
Oncodevelopmental Biology and Medicine 2, 305-311 (1981).
- 79 Powles TJ  
Adjuvant Therapy in Breast Cancer

- IN Breast Cancer Management. Ed RC Coombes, TJ Powles, HT Ford, JC Gazet Pubs. Academic Press Inc. London Ltd (1981) pp 137-152
- 80 Dady PJ, Powles TJ, Dowsett M, Easty G, Williams J, Neville AM In vitro osteolytic activity of human breast carcinoma tissue and prognosis  
Br J Cancer 43, 222-225 (1981)
- 81 Coombes RC, Powles TJ  
Tumour Markers in the management of human cancer  
IN Topical Reviews in Radiotherapy and Oncology Ed TJ Deeley, Pubs. John Wright & Son Ltd, Bristol (1981) pp 39 - 65
- 82 Powles TJ, Smith IE, Coombes RC  
Endocrine therapy and cancer.  
IN Cancer Treatment. Ed KE Halnan, Publishers Chapman and Hall, London pp103-118 (1981)
- 83 Harris AL, Smith IE, Dowsett M, Jeffcote SJ, Coombes RC, Powles TJ, Neville AM  
Sex hormone binding globulin levels and prognosis in early breast cancer  
Letter Lancet 1, 8214: 279 (1981)
- 84 Coombes RC, Powles TJ, Gazet J-C, Ford HT, McKinna A, Abbott M, Gehrke CW, Keyser JW, Mitchell PEG, Patel S, Stimson WH, Worwood M, Jones J, Neville AM  
Screening for metastases in breast cancer: An assessment of biochemical and physical methods  
Cancer 48, 310-315 (1981)
- 85 Powles TJ  
Endocrine therapy of breast cancer  
IN Breast Cancer Management Ed RC Coombes TJ Powles, HT Ford, J-C Gazet Pubs Academic Press, London pp171-187 (1981)
- 86 Jones S, Moon T, Davis S, Valagussa P, Bonadonna G, Powles T, Rivkin S  
Comparative analysis of selected breast cancer adjuvant trials in relation to the natural history data base (NHDB)  
IN Adjuvant Therapy of Cancer III Eds Jones & Salmon, Pubs Grune & Stratton pp. 483-491 (1981)
- 87 Powles TJ  
Survival of patients with metastatic breast cancer treated with aminoglutethimide compared to patients treated with cytotoxic chemotherapy.  
IN Aminoglutethimide. Mechanism of action and clinical results in breast cancer. Ed. FJA Paesi, pp.95-98 (1981)
- 88 Powles TJ  
Adjuvant Endocrine Therapy.

- IN Adjuvant Therapy of Cancer III. Eds. Jones & Salmon. Pubs. Grune & Stratton. p. 305-311 (1981).
- 89 Powles TJ  
Adjuvant therapy for primary breast cancer. Editorial  
Clinical Oncology 7, 79-81 (1981)
- 90 Powles TJ  
Adjuvant therapy of breast cancer  
IN Breast Cancer Ed M Baum. Publishers: Update Publications Limited p 20-23 (1981)
- 91 Moon T, Jones S, Davis S, Bonadonna G, Valagussa P, Veronesi U, Powles T  
Development of a natural history data base for breast cancer. In Adjuvant Therapy of Cancer III Eds Jones & Salmon Pub: Grune & Stratton (1981) pp 471-481.
- 92 Millar BC, Jinks S, Powles TJ  
Flurbiprofen, a non-steroidal anti-inflammatory agent, protects cells against hypoxic cell radiosensitizers in vitro.  
Br J Cancer, 44 733-739 1981
- 93 Dearnaley DP, Sloane JP, Ormerod MG, Steele K, Coombes RC, Clink H, Powles TJ, Ford HT, Gazet J-C, Neville AM  
Increased detection of mammary carcinoma cells in marrow smears using anti-sera to epithelial membrane antigen.  
Br J Cancer 44, 85 (1981)
- 94 Powles TJ, Coombes RC  
Mechanisms of action of Danazol  
Cancer Chemotherapy & Pharmacology 6, 101 (1981)
- 95 Smith IE, Powles TJ, Coombes RC, Ford HT, Gazet J-C, Harmer CL and McKinna JA  
A control randomised trial comparing vindesine and adriamycin with vincristine and adriamycin in the treatment of advanced breast carcinoma.  
IN Contributions to Oncology. Eds. W. Brade, G.A. Nagel, S. Seeber 6, 185-187 (1981)
- 96 Taylor RE, Powles TJ, Humphreys J, Bettelheim R, Dowsett M, Casey AJ, Neville AM and Coombes RC  
Effects of Endocrine Therapy on Steroid-Receptor Content of Breast Cancer  
Br J Cancer 45, 80 (1982)
- 97 Rowland-Payne, C, Abbott M, Jones JM, Powles TJ, Coombes RC Weight loss during therapy for advanced breast cancer.  
Clinical Oncology, 8, 33-38 (1982)
- 98 Powles TJ, Coombes RC, Depledge M, Muindi J, Powles RL  
Prostaglandin Administration to patients with cancer

- IN Prostaglandins and Cancer Eds Powles TJ, Buckman RS, Honn KV, Ramwell P  
Pubs Liss, New York pp 825-830 (1982) pp 825-830
- 99 Heckford Susan E, Eccles Suzanne A, Powles TJ and Alexander P.  
Failure of Flurbiprofen to enhance the therapeutic effect of cyclophosphamide  
Br J Cancer 46(1): 51-57 (1982)
- 100 Powles TJ, Muindi J, Coombes RC  
Mechanisms for development of bone metastases and effects of anti-inflammatory  
drugs.  
IN Prostaglandins and Cancer: Ed Powles TJ, Buckman RS, Honn KV, Ramwell P  
Pubs Alan R Liss Inc, NY pp 541-553 (1982)
- 101 Powles TJ, Gordon C, Coombes RC  
Clinical trial of multiple endocrine therapy for metastatic and locally advanced breast  
cancer with Tamoxifen-Aminoglutethimide-Danazol compared to Tamoxifen used  
alone Cancer Research Supplement 42 3458-3460 (1982)
- 102 Powles TJ, Coombes RC, Gordon C, Smith IE  
Vindesine in combination with adriamycin for treatment of metastatic breast cancer.  
Drugs Exptl Clin Res (5) 571-575 (1982)
- 103 Coombes RC, Powles TJ, Rees LH, Ratcliffe WA, Nash AG, Henk JM, Ford HT, Gazet  
J-C, Neville AM  
Tamoxifen, aminoglutethimide and danazol: Effect of therapy on hormones in post  
menopausal patients with breast cancer.  
Br J Cancer 46, 30-34 (1982)
- 104 Coombes RC, Chilvers Clair, Dowsett M, Gazet J-C, Ford HT, Bettelheim R, Gordon  
C, Smith IE, Zava D, Powles TJ  
Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast  
cancer: Progress Report  
  
Cancer Research (Suppl) 42 3415-3419 (1982)
- 105 Heckford Susan E, Eccles SA, Powles TJ and Alexander P  
Flurbiprofen does not appear to enhance the therapeutic effect of cyclophosphamide.  
IN Prostaglandins and Cancer: Eds Powles TJ, Buckman RS, Honn KV and Ramwell  
P Pubs Alan R Liss Inc, NY pp 815-817 (1982)
- 106 Millar BC, Jinks S, Powles TJ  
Protection against misonidazole-induced toxicity in vitro by flurbiprofen, a  
non-steroidal anti-inflammatory agent.  
IN Prostaglandins and Cancer: Eds Powles TJ, Bockman RS, Honn KV and Ramwell  
P Pubs Alan R Liss, Inc, NY pp 793-797 (1982)
- 107 Powles TJ

- Present role of hormonal therapy.  
 IN Breast Cancer: Recent Advances in Diagnosis and Treatment. Ed G Bonadonna,  
 Pubs John Wiley & Sons Ltd pp 229-246 (1982).
- 108 Harris AL, Powles TJ, Smith IE  
 Aminoglutethimide in the Treatment of Advanced Postmenopausal Breast Cancer  
 Cancer Research (Suppl) 42 34O5-34O8 (1982)
- 109 Powles TJ, Coombes RC, Gordon C and Smith IE  
 A comparison of vindesine vs. vincristine with adriamycin for treatment of patients with  
 metastatic or locally recurrent breast cancer.  
 Eighth Vinca Alkaloid Symposium - Vindesine. ED Marie T Bakowski. Publishers Ely  
 Lilly pp 65-79 (1982)
- 110 Powles TJ  
 Adjuvant Endocrine Therapy.  
 Reviews on Endocrine - Related Cancer Suppl 12, 37-40, (1982).
- 111 Coombes RC, Dearnaley DP, Buckman R, Jones JM, Ormerod MG, Sloane JP, Powles  
 TJ, Gazet JC, Ford HT, Neville AM  
 Detection of bone metastases in patients with breast cancer.  
 Invasion Metastasis, 2, 177-184, (1982).
- 112 Powles TJ  
 Administration of prostaglandins A and anti-inflammatory drugs to patients with cancer.  
 IN Advances in Prostaglandin and Thromboxane Research 12, 327-331 (1983)
- 113 Coombes RC, Dady P, Parsons C, Ford HT, Gazet J-C, Powles TJ Assessment of  
 response of bone metastases to systemic treatment in patients with breast cancer.  
 Cancer 52: 610-614 (1983)
- 114 Coombes RC, Perez D, Gazet JC, Ford HT and Powles TJ  
 Danazol treatment for advanced breast cancer.  
 Cancer Chemother & Pharmacol, 10 194-195 (1983)
- 115 Harris AL, Mitchell M, Smith IE, Powles IE  
 Suppression of plasma 6-Keto-Prostaglandin F and 13, 14-dihydro-15-keto-  
 prostaglandin F by aminoglutethimide in advanced breast cancer  
 Br J Cancer (1983) 48, 595-598
- 116 Muindi J, Coombes RC, Golding S, Powles TJ, Khan O and Husband J  
 The role of computed tomography in the detection of bone metastases in breast cancer  
 Br J Radiol 56 233-236 (1983)
- 117 Powles TJ, Coombes RC, Harris AL and Smith IE Aminoglutethimide with  
 hydrocortisone for treatment of disseminated breast cancer

- IN Aminoglutethimide Eds RW Elsdon-Dew, IM Jackson, GFB Birdwood Pubs Roy Soc of Med Academic Press Inc (London) Limited, Grune & Stratton Inc, NY pp 41-42 (1983)
- 118 Coombes RC, Chilvers C, Dowsett M, Bettelheim R, Gordon C, Smith IE, Zava D and Powles TJ  
Aminoglutethimide as an adjuvant to surgery in poor risk postmenopausal patients with breast cancer.  
IN Aminoglutethimide Eds. R.W. Elsdon-Dew, I.M. Jackson, G.F.B. Birdwood, Pubs. Roy. Soc. of Med. Academic Press Inc. (London) Limited, Grune & Stratton, Inc., N.Y. pp 37-39 (1983)
- 119 Harris AL, Powles TJ, Smith IE, Coombes RC, Ford HT, Gazet J-C, Harmer CL, Morgan M, White H, Parsons CA and McKinna JA Aminoglutethimide for the treatment of advanced postmenopausal breast cancer.  
Eur J Cancer Clin Oncol 19(1) pp 11-17 (1983)
- 120 Perez DJ, Powles TJ, Milan J, Gazet J-C, Ford HT, McCready VR, MacDonald JS and Coombes RC  
Detection of Breast Carcinoma Metastases in Bone: The Relative Merits of X rays and Skeletal Scintigraphy.  
Lancet II 613-616 (1983)
- 121 Coombes RC, Powles TJ, Buckman R, Skilton R, McClelland R, Hunt J, Redding WH and Neville AM  
Medical Management of Breast Cancer.  
IN Symposium on Medical Management of Malignant Disease  
Proc. Symposium, Royal College of Physicians of Edinburgh, 37-47, (1983).
- 122 Powles TJ and Nash AG  
Latissimus dorsi reconstruction of the breast (Letter)  
BMJ 287, 1225-1226 (1983)
- 123 Powles TJ  
The Role of Aromatase Inhibitors in Breast Cancer  
Seminars in Oncology (1983)
- 124 Redding WH, Coombes RC, Monaghan P, Clink HMcD, Imrie SF, Dearnaley DP, Ormerod MG, Sloane JP, Gazet J-C, Powles TJ and Neville AM  
Detection of micrometastases in patients with primary breast cancer.  
Lancet 1271-1274 (1983)
- 125 Morris AJR, O'Sullivan JP, Millard FJC, Humberstone AM, Hunt J, Gazet J-C, Powles TJ, Ford HT and Coombes RC  
Fibreoptic bronchoscopy as an aid to diagnosis of respiratory symptoms in breast cancer patients.  
Br J Cancer 48 731-734 (1983)

- 126 Perez DJ, Powles TJ, Gazet J-C, Ford HT and Coombes RC Mitomycin C, melphalan and methotrexate combination chemotherapy for palliation of disseminated breast cancer.  
Cancer Chemother and Pharmacol 13 36-38 (1984)
- 127 Powles TJ  
Clinical trials with Endocrine therapy in Advanced Disease.  
IN Clinical Trials in Cancer Medicine. Pub. Academic Press. Eds G Bonnadonna and U Veronesi (1984) 335-342
- 128 Powles TJ, Ashley S, Ford HT, Gazet J-C, Nash AG, Neville AM and Coombes RC  
Treatment of Disseminated Breast Cancer with Tamoxifen, Aminoglutethimide, Hydrocortisone and Danazol, used in Combination or Sequentially.  
Lancet II, 1369-1373 (1984)
- 129 Heusinkveld, R., Valagussa, P., Bonnadonna, G., Powles, T.J. Is T<sub>3</sub>NoMo Breast Cancer with Pathologically Negative Nodes Truly Stage III?  
JCO 242-243 (1984)
- 130 Coombes RC, Powles TJ, Easton D, Chilvers CED, Ford HT, Smith IE, McKinna A, White H, Bradbeer J, Yarnold J, Nash A, Bettleheim R, Dowsett M, Gazet J-C.  
Adjuvant Aminoglutethimide therapy for postmenopausal patients with primary breast cancer. Breast Cancer: Therapeutic Modalities Current and Future. Eds Harvey HA, Lipton A, Michaels MA, Pubs MES Medical Education Services (Canada) Toronto, 61-66 (1984)
- 131 Perez DJ and Powles TJ  
Breast conservation and its integration with adjuvant chemotherapy and adjuvant hormone therapy. IN Breast Conservation in the Management of Breast Cancer. Eds Peckham M and Tobias J Pubs Ed Arnold pp 165-178 (1985)
- 132 Perez DJ, Powles TJ, Smith IE, Vincent M, Ashley Susan, Gordon C, Gibb J, Clarke S, Coombes RC The Modulating Effects of Flurbiprofen on Adriamycin plus Vincristine, or Vindesine in the Treatment of Advanced Breast Cancer.  
Cancer Chemother & Pharmacol, 15, 278-282, (1985)
- 133 Gazet J-C, Rainsbury RM, Ford HT, Powles TJ and Coombes RC Survey of Treatment of Primary Breast Cancer in Great Britain.  
British Medical Journal 290, 1793-1795 (1985)
- 134 Coombes RC, Powles TJ, Muindi J, Hunt J, Ward M, Perez D and Neville AM  
Trilostane therapy for advanced breast cancer  
Cancer Treatment Reports 69, 351-354 (1985)
- 135 Vincent MD, Clink H, Coombes RC, Smith IE, Kandler R and Powles TJ

- Aminoglutethimide (with hydrocortisone) induced agranulocytosis in patients with primary breast cancer.  
British Medical Journal 291, 105-106 (1985)
- 136 Powles TJ, Ashley S, Adcock H, Thomas L and Coombes RC Therapy of disseminated breast cancer with antioestrogens, sequentially or in combination with other hormones  
Excerpta Medica 31, 198-205, (1985)
- 137 Waxman JH, Harland SJ, Coombes RC, Wrigley PFM, Malpas JS, Powles TJ, Lister TA  
The treatment of postmenopausal women with advanced breast cancer with Buserelin.  
Cancer Chemotherapy and Pharmacology, 15, 171-173 (1985)
- 138 Powles TJ  
Criteria for Assessment of Response of Bone Metastases to Systemic Therapy.  
IN Bone Resorption Metastases and Diphosphonates. Pub. Raven Press, NY Eds. Garrotini, S 93-108 (1985)
- 139 Powles TJ  
Patterns and Mechanisms of bone metastases  
Proc Roy Soc Med 1985; 78: 1
- 140 McClelland RA, Berger U, Miller LS, Powles TJ, Jensen EV, Coombes RC  
Immunocytochemical Assay for Oestrogen Receptor: Relationship to outcome of therapy in patients with advanced breast cancer.  
Cancer Research (Suppl) 46, 4241-4243 (1986)
- 141 Powles TJ, Coombes RC, Smith IE, Chilvers C, Easton D, Thomas L, Adcock H, Gazet J-C, Nash AG, Bradbeer J, McKinna JA  
A double blind randomised clinical trial of adjuvant amino- glutethimide versus placebo given to post menopausal patients with histologically confirmed stage II breast cancer.  
Breast Cancer Research and Treatment, 7, 37-40 (1986)
- 142 Coombes RC, Buckman R, Forrester JA, Shepherd V O'Hare MJ, Vincent M, Powles TJ, Neville AM  
In Vitro and in vivo effects of a monoclonal antibody-toxin conjugate for use in autologous bone marrow transplantation for patients with breast cancer.  
Cancer Research 46, 4217-4220, (1986)
- 143 Goss PE, Ashley S, Powles TJ, Coombes RC  
High Dose Oral Medroxyprogesterone Acetate in Heavily Pretreated Patients with Metastatic Breast Cancer.  
Cancer Treatment Reports, 70, 777-779 (1986)
- 144 Coombes RC, Berger U, Mansi J, Redding H, Powles TJ, Neville AM, McKinna A, Gazet J-C, Ford HT, Omerod M, McDonnell T  
Prognostic Significance of Micrometastases in Bone Marrow in patients with primary breast cancer. NCI

- Monographs Adjuvant Chemotherapy and Endocrine Therapy for Breast Cancer, 1, 51-53, (1986).
- 145 Goss PE, Powles TJ, Dowsett M, Hutchison GB, Angela MH, Coombes RC  
Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4 - hydroxyandrostenedione - Phase II report.  
Cancer Research 46, 4823-4826 (1986)
- 146 Vincent MD, Powles TJ, Skeet R, Ashley S, Coombes RC, Gibb J, Clarke S, Thomas HL, Adcock H An analysis of possible prognostic features of long term and short term survivors of metastatic breast cancer.  
Eur J Cancer 22, 1059-1065 (1986)
- 147 Dowsett M, Goss PE, Powles TJ, Hutchinson G, Brodie AMH, Jeffcoate SL, Coombes RC  
Use of the Aromatase inhibitor, 4 hydroxyandrostenedione in postmenopausal breast cancer: Optimisation of therapeutic dose and route.  
Cancer Research, 47, 1957-1961 (1987)
- 148 Powles TJ  
Prostaglandins and Cancer: Clinical Approaches.  
IN Prostaglandins in Cancer Research Eds Garaci E, Paoletti R, Santoro MG, Pubs Springer-Verlag, Berlin, 184-189 (1987)
- 149 Powles TJ  
The role of hormonal manipulation in the management of breast cancer.  
IN Current Management of Breast Cancer, Toronto: MES Medical Education Services. Eds. Margolese, R. Pubs. Citation, 8-9, (1987)
- 150 Powles TJ, Ford HT, Gazet J-C  
A Randomised Clinical Trial to compare Tamoxifen with Danazol for treatment of benign mammary dysplasia  
Breast Diseases - Senologia, 2: 1-5 (1987)
- 151 Powles TJ, Ashley S, Forgeson GV, O'Keefe A, Richards L, Gallagher C, Coombes RC  
Treatment of Advanced Breast Cancer with Mitocycin C, Mitozantrone and Methotrexate (MMM) compared to vincristine, anthracycline and cyclophosphamide (VAC).  
IN Clinical Progress with Mitozantrone. Eds. G. Bonadonna. Pubs Royal Soc Med Services London, New York. Series No 110, 1-7, (1987)
- 152 Mansi JL, Powles TJ, Coombes RC  
The Detection and Evaluation of Bone Marrow Micrometastases in Primary Breast Cancer.  
In Fundamental Problems in Breast Cancer. Eds. Patterson, AGH Pubs Martinus Nijhoff, 299-301 (1987)

- 153 Powles TJ  
Treatment of Metastatic Breast Cancer as a guide to design of Adjuvant Therapy Trials.  
In *Fundamental Problems in Breast Cancer*. Eds. Patterson, AGH Pubs Martinus  
Nijhoff, 369-372 (1987)
- 154 Powles TJ  
Endocrine Prevention of Breast Cancer by Tamoxifen  
IN *Fundamental Problems in Breast Cancer*. Eds Patterson AGH Pubs Martinus  
Nijhoff, 139-143, (1987)
- 155 Powles TJ  
The role of hormonal manipulation in the management of breast cancer.  
In *Current Management of breast cancer*, Toronto: MES Medical Education Services  
Eds Margolese R Pubs Citation, 8-9 (1987)
- 156 Powles TJ, Gallagher CJ, Ashley SE, Fenlon D, O'Keeffe AP Mitomycin C used in  
combination with Mitozantrone and Methotrexate as first line cytotoxic treatment of  
disseminated breast cancer. IN *New Trends in Cancer Chemotherapy with Mitomycin  
C* Eds Taguchi T, Andrysek O. Pubs Excerpta Medica, 51-57, (1987)
- 157 Bellamy EA, Nicholas D, Ward M, Coombes RC, Powles TJ, Husband JE  
Comparison of Computed Tomography and Conventional Radiology in the assessment  
of treatment response of lytic bony metastases in patients with carcinoma of the breast.  
*Clinical Radiology* 38, 351-355, (1987).
- 158 Fentiman IS, Powles TJ  
Tamoxifen and Benign Breast Problems  
*Lancet* II, 1070-1072, (1987)
- 159 Powles TJ, Coombes RC, Berger U, McClelland RA, Trott PA, Wilson P, Gazet J-C,  
Ford HT Prediction of endocrine response in breast cancer by immunocytochemical  
detection of oestrogen receptor in fine needle aspirates.  
*Lancet* II, 701-703, (1987)
- 160 Cunningham D, Powles TJ, Dowsett M, Hutchison G, Brodie AMH, Ford HT, Gazet J-  
C, Coombes RC  
Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast  
cancer.  
*Cancer, Chemother and Pharmacol* 20, 253-255, (1987)
- 161 Jones SE, Moon TE, Bonadonna G, Valagussa P, Rivkin S, Buzdar A, Montague E,  
Powles TJ Comparison of different trials of adjuvant chemotherapy in stage II breast  
cancer using a natural history data base (NHDB).  
*Am J Clin Oncol* 10 (5): 387-395, (1987)

- 162 McClelland RA, Berger U, Wilson P, Powles TJ, Trott PA, Easton D, Gazet J-C, Coombes RC Presurgical determination of estrogen receptor status using immunocytochemically stained fine needle aspirate smears in patients with breast cancer.  
Cancer Research, 47, 6118-6122, (1987)
- 163 Coombes RC, Powles TJ, Easton D, Chilvers C, Ford HT, Smith IE, McKinna A, White H, Bradbeer J, Yarnold J, Nash AG, Bettelheim R, Dowsett M, Gazet J-C and Investigators of the Collaborative Breast Cancer Project.  
Adjuvant aminoglutethimide therapy for post-menopausal patients with primary breast cancer Cancer Research, 47, 2496-2499, (1987)
- 164 Vincent MD, Powles TJ, Ford HT, Gazet JC  
Excision of solitary lung metastases from two patients with breast cancer  
Br J Surgery 74, 194 (1987)
- 165 Powles TJ, Ashley SE  
Myelosuppression after methotrexate, mitozantrone and mitomycin C for the treatment of advanced breast cancer. (Letter)  
Lancet ii 853 (1987).
- 166 Mansi JL, Berger V, Easton D, McDonnell T, Redding WH, Gazet J-C, McKinna A, Powles TJ, Coombes RC  
Bone marrow micrometastases in patients with primary breast cancer: An early predictor of bone metastases.  
British Medical Journal, 295, 1093-1096, (1987).
- 167 Powles TJ  
Advanced breast cancer - New approaches to treatment.  
Eur J Clinical Clin Oncol, 24, 95-98, (1988)
- 168 Mansi JL, Earl H, Powles TJ, Coombes RC  
Tests for detecting recurrent disease in the follow up of patients with breast cancer.  
Breast Cancer Research and Treatment, 11, 249-254, (1988)
- 169 Vincent MD, Powles TJ, Coombes RC, McElwain TJ  
Late intensification with high dose melphalan and autologous bone marrow support in breast cancer patients responding to conventional chemotherapy.  
Cancer Chemother and Pharmacol 21, 255-260, (1988)
- 170 Gusterson BA, Gullick WJ, Venter DJ, Powles TJ, Elliott C, Ashley SE, Tidy VA, Harrison S  
Immunohistochemical localisation of C-erbB-2 in human breast carcinoma.  
Molecular and Cellular Probes 2, 383-391, (1988)

- 171 Gusterson BA, Machin LG, Gullick WJ, Gibbs NM, Powles TJ, Price P, McKinna A, Harrison S Immunohistochemical distribution of C-erbB-2 in infiltrating and in situ breast cancer.  
Int J Cancer 42, 842-845 (1988)
- 172 Travers MT, Barrett-Lee PJ, Berger U, Luqmani YA, Gazet J-C, Powles TJ, Coombes RC  
Growth factor expression in normal, benign and malignant breast tissue.  
British Medical Journal 296, 1621-1624, (1988).
- 173 Gusterson BA, Machin LG, Gullick WJ, Gibbs NM, Powles TJ, Elliott C, Ashley S, Monaghan P, Harrison S  
c-erbB-2 expression in benign and malignant breast disease.  
Br J Cancer 58, 453-457 (1988)
- 174 Hardy JR, Powles TJ, Coombes RC, Ashley S  
Epirubicin compared with doxorubicin with vincristine and cyclophosphamide in advanced breast cancer.  
Proceedings of the Pharmorubicin Update 1988 Symposium. Pubs Medicom (UK) Ltd. pp 37-41
- 175 Powles TJ  
Treatment of menopausal symptoms in breast cancer patients.  
Lancet ii 344-345 (1988) Letter
- 176 Powles TJ, Davey JB, McKinna A  
A Feasibility trial of tamoxifen chemoprevention of breast cancer in Great Britain.  
Cancer Investigation 6(5) 621-624 (1988)
- 177 Nash AG, Powles TJ  
Review of a hospital experience of breast abscesses  
Br J Surgery 76 103 (1989)
- 178 Powles TJ, Hardy JR, Ashley SE, Farrington GM, Cosgrove D, Davey JB, Dowsett M, McKinna JA, Nash AG, Sinnott HD, Tillyer CR, Treleaven JG  
A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer  
Br J Cancer 60 126-131 (1989)
- 179 Olliff JFC, Hardy JR, Williams MP, Powles TJ  
Case Report: Magnetic resonance imaging of spinal amyloid.  
Clinical Radiology (1989) 40, 632-633
- 180 Lonning PE, Dowsett M, Powles TJ  
Treatment of breast cancer with aromatase inhibitors - current status and future prospects  
Br J Cancer 60, 5-8 (1989)

- 181 Powles TJ  
Oral contraceptives and breast cancer  
Lancet ii 97 (1989) Letter
- 182 Powles TJ, Hardy JR, Ashley SE, Cosgrove D, Davey JB, Dowsett M, McKinna JA, Nash AG, Rundle SK, Sinnett HD, Tillyer CR, Treleaven JG  
Chemoprevention of breast cancer  
Breast Cancer Res Treatment 14 23-31(1989)
- 183 Powles TJ, Davey J, McKinna A  
Chemoprevention of breast cancer  
Acta Oncologica 28 865-867 (1989)
- 184 Powles TJ, Jones AL, Ashley SE, Tidy A  
Menstrual effect on surgical cure of breast cancer - Letter  
Lancet ii 1343-1344 (1989)
- 185 Lonning PE, Dowsett M, Jacobs S, Schem B, Hardy J, Powles TJ  
Lack of diurnal variation in plasma levels of androstenedione, testosterone, estrone and estradiol in postmenopausal women  
J Steroid Biochem 34, 551-553 (1989)
- 186 Lonning PE, Dowsett M, Powles TJ  
Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for treatment of breast cancer.  
Steroid Biochemistry 35, 355-366 (1990)
- 187 Jones AL, Williams MP, Powles RJ, Oliff JFC, Hardy JR, Cherryman G, Husband J  
Magnetic resonance imaging in the detection of skeletal metastases in patients with breast cancer  
Br J Cancer 62, 296-298 (1990)
- 188 Powles TJ  
Tamoxifen breast cancer remission: estrogenic or antiestrogenic?  
Oncology News 16, 7 (1990)
- 189 Svensson WE, Al-Murrani B, Blaszczyk M, Cosgrove DO, Hounsom A, Jones A, Powles TJ, Sinnett HD, Tohno E, Vagios E  
Confusing appearances on breast ultrasound caused by fine needle aspiration  
Br J Radiol 63, 400 (1990)
- 190 Hardy JR, Powles TJ, Judson IR, Sinnett D, Ashley SE, Coombes RC, Ellin CL  
Combination hormone treatment with tamoxifen, aminoglutethimide, danazol and medroxyprogesterone acetate in advanced breast cancer  
Eur J Cancer Vol 26, 7, 824-827 1990

- 191 Powles TJ (Overview)  
Tamoxifen and oestrogen replacement (Letter)  
*Lancet* ii (1990) 336 48
- 192 Hardy JR, Powles TJ, Judson I, Heron C, Williams M, Cherryman G, Husband J, Cosgrove D, Blaszczyk M, Sinnett HD, Ashley SE, Trott PA  
How many tests are required in the diagnosis of palpable breast abnormalities?  
*Clinical Oncology* 2, 148-152 (1990)
- 193 Powles TJ  
Metastatic breast cancer  
*Oncology Commentary* 3: 1-2 (1990)
- 194 Powles TJ, Tillyer CR, Jones AL, Ashley SE, Treleaven J, Davey JB, McKinna JA  
Prevention of breast cancer with tamoxifen - an update on the Royal Marsden Hospital pilot programme  
*Eur J Cancer* 26, 680-684, 1990
- 195 Brada M, Rowley M, Grant DJ, Ashley S, Powles TJ  
Hypercalcaemia in patients with disseminated breast cancer  
*Acta Oncologica* 29 577-580 1990
- 196 Jones AL, Spyrou N, Rawley M, Powles TJ  
Ranitidine induced thrombocytopenia and pancytopenia in patients on prophylactic ranitidine  
*Eur J Int Med* 2: 183-185 (1991)
- 197 Powles TJ, Trott PA, S, Cherryman G, Clarke S, Ashley S, Coombes RC, Jones AL, Sinnett HD, Nash AG  
Fine needle aspiration cytodiagnosis as a pre requisite for primary medical treatment of breast cancer  
*Cytopathology* 2, 7-12 (1991)
- 198 Jones AL, Forgeson GV, Powles TJ, Coombes RC  
A clinical study of nafazatrom in advanced human breast cancer  
*Cancer Chemother Pharmacol* (1991) **27(4)**: 326-8
- 199 Powles TJ, Jones AL, Judson IR, Hardy JR, Ashley SE  
A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer  
*Br J Cancer*, 64; 406-410, (1991)
- 200 Haynes BP, Jarman M, Dowsett M, Mehta A, Lonning PE, Griggs LJ, Jones A, Powles T, Coombes RC  
Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in postmenopausal breast cancer patients

- Cancer Chemother Pharmacol (1991) 27: 367-372
- 201 Jones AL, Dowsett MJ, Powles TJ, Gallagher CJ, Coombes RC  
Treatment of advanced breast cancer with miconazole: a potential inhibitor of peripheral oestrogen synthesis  
Eur J Cancer 27(3) 301 (1991)
- 202 Jones AL, Powles TJ  
The use of tamoxifen in malignant breast disease  
Maternal & Child Health 16; 116-119 (1991)
- 203 Jones AL, Powles TJ  
Antiosteolytic treatments for skeletal metastases: General principles and clinical results  
In Tumour induced hypercalcaemia and its management  
Eds Russell RGG, Kanis JA  
Royal Society of Medicine Services Ltd, London, New York  
71-92 (1991)
- 204 Lonning PE, Jacobs S, Jones A, Haynes B, Powles T, Dowsett M  
The influence of CGS16949A on peripheral aromatisation in breast cancer patients  
Br J Cancer **63**: 789-93 (1991)
- 205 Jones AL, Powles TJ  
Chemoprevention of breast cancer with tamoxifen  
IN Medical Management of Breast Cancer. Eds Powles TJ and Smith IE  
Publisher Martin Dunitz 1991. pp 161-166.
- 206 Paterson AHG, Ernst DS, Powles TJ, Ashley S, Kanis JA, McCloskey EV  
The use of clodronate in patients with breast cancer  
Eur J Cancer (Suppl) - In press 1991
- 207 Dowsett M, MacNeill F, Mehta A, Newton C, Haynes B, Jones A, Jarman M, Lonning PE,  
Powles TJ, Coombes RC  
Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-thyl-3-(4-pyridyl)piperidine-2,6-dione ("pyridoglutethimide") in postmenopausal breast cancer patients  
British Journal of Cancer (1991) **64**: 887-894
- 208 Powles TJ  
Talking point - On trial: Drugs that may prevent disease  
New Scientist 1752, 16 1991
- 209 Powles TJ  
Clodronate: the potential for the future  
Bone, 12, (Suppl. 1) S43-S44 1991

- 210 Powles TJ  
Prevention of breast cancer  
Current Opinion in Oncology (1991) 3: 1024-1028
- 211 Glaholm J, Collins D, Mansi J, Sharp JC, Leach MO, McCready VR, Smith IE, Powles T, Hind AJ  
The importance of signal localisation and measurement of absolute metabolite changes when monitoring the treatment response of human breast carcinoma with in-vivo <sup>31</sup>P NMR spectroscopy  
In Radioaktive Isotope in Klinik und Forschung. Eds R Höfer, H Bergmann and H Sinzinger. Schuattauer Stuttgart New York, 158-164, (1991)
- 212 Powles TJ, Gazet JC, Ford HT, Ashley SE, Nash AG, Tidy VA  
Timing of Surgery for premenopausal breast cancer in relation to the last menstrual period (Letter)  
Lancet, 337: 1603-1604 (1991)
- 213 Jones AL, Powles TJ  
Chemoprevention of Breast Cancer with Tamoxifen  
Chemoimmunoprevention of Cancer. Eds: Pastorio U & Hong WK. Thieme Medical Publishers, Inc., New York 225-229, (1991)
- 214 Paterson AHG, Ernst DS, Powles TJ, Ashley S, McCloskey EV, Kanis JA  
Treatment of skeletal disease in breast cancer with clodronate  
Bone, 12 (suppl. 1), S25-S30, (1991)
- 215 Dowsett M, Mehta A, King N, Smith IE, Powles TJ, Stein RC, Coombes RC  
An endocrine and pharmacokinetic study of 4 oral doses of 4-hydroxyandrostenedione in postmenopausal breast cancer patients  
Eur J Cancer, 28, 415-420, 1992
- 216 Jones AL, MacNeill F, Jacobs S, Lonning PE, Dowsett M, Powles TJ  
The influence for intramuscular 4 hydroxyandrostenedione on peripheral aromatisation in breast cancer patients  
Eur J Cancer, 28: 1712-1716, 1992
- 217 Powles TJ, Smith IE (Letter on overview)  
Adjuvant treatment in breast cancer  
Lancet, **339**, 423, (1992)
- 218 Bliss JM, Selby PJ, Robertson B, Powles TJ  
A method for assessing the quality of life of cancer patients: replication of the factor structure  
Brit J Cancer, 65: 961-966 (1992)
- 219 Talbot DC, Smith IE, Nicolson M, Powles TJ, Button D, Walling J

- A phase II trial of the novel sulphonylurea sulofenur (LY186641) in advanced breast cancer  
*Cancer Chemotherapy & Pharmacology*, 35(5): 419-422 (1992)
- 220 Jones AL, Powles TJ, Treleavan J, Burman JF, Nicolson MC, Chung H-I, Ashley SE  
Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women  
*Brit J Cancer*, 66; 744-747, (1992)
- 221 Jones AL, Powles TJ, Law M, Tidy A, Easton D, Coombes RC, Smith IE, McKinna JA, Nash A, Ford HT, Gazet JC  
Adjuvant Aminoglutethimide for post-menopausal patients with primary breast cancer: analysis at eight years  
*J Clin Oncol*, **10**: 1547-1552, (1992)
- 222 Lønning PE, Dowsett M, Jones A, Ekse D, Jacobs S, MacNeill F, Johannsen DC, Powles TJ  
Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-Hydroxyandrostenedione treatment  
*Breast Cancer Research & Treatment*, 23: 57-62, 1992
- 223 Powles TJ  
Tamoxifen in the endocrine prevention of breast cancer  
*Endocrine Aspects of Breast Cancer*, 37-39, (1992)
- 224 Jones AL, Powles TJ  
The development of cancer chemoprevention trials  
In: *Introducing New Treatments for Cancer: Practical, Ethical and Legal Problems*.  
Ed: Williams CJ, John Wiley & Sons, England (1992)
- 225 MacNeill FA, Jones AL, Jacobs S, Lønning PE, Powles TJ, Dowsett M  
The influence of Aminoglutethimide and its analogue Rogletimide on peripheral aromatisation in breast cancer  
*Brit J Cancer*, 66:692-697, 1992
- 226 Powles TJ  
The case for clinical trials of tamoxifen for prevention of breast cancer - A Personal View  
*Lancet*, 340: 1145-47, 1992
- 227 Ricketts D, Hadcocks L, Fitzek M, Rawson NSB, Colston K, Powles TJ, Gazet J-C, Coombes RC  
Serum markers for primary and recurrent breast cancer; BCM-EIA, CAM 26 and CAM 29  
*Tumour Biology* (1992) **13**: 207-216
- 228 Powles TJ

Current Controversies in the Endocrine Therapy of Advanced Breast Cancer  
Oncology 1992; **49**: 18-21

- 229 Nicolson MD, Powles TJ  
Treatment of metastatic bone disease with clodronate  
Therapy Express, 1992; **51**: 1-6
- 230 Jacobs S, MacNeill F, Lonning P, Dowsett M, Jones A, Powles TJ  
Aromatase activity, serum oestradiol and their correlation with demographic indices  
J Steroid Biochem Mol Biol 41 769-771 (1992)
- 231 Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley SE  
Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer  
J Clin Oncol **11**(1): 59-65 (1993)
- 232 Montes A, Powles TJ, O'Brien MER, Ashley SE, Luckitt J, Treleavan J  
A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome  
Eur J Cancer **29A**(13): 1854-57, 1993
- 233 Jones AL, Powles TJ  
Breast cancer chemoprevention  
Current Practice in Surgery 1993; **5**: 162-165
- 234 Powles TJ  
Prevention of metastases with bisphosphonates  
Canadian Journal of Diagnosis 1993; (supplement) 37-40
- 235 Powles TJ, Hickish T, Casey S, O'Brien M,  
Hormone replacement therapy after breast cancer - Letter  
Lancet **342**: 60-61 (1993)
- 236 O'Brien ME, Powles TJ  
Tamoxifen in the prevention of breast cancer: Are the Risks likely to outweigh the benefits?  
Drug Saf (1993) **10**: 1-4
- 237 Powles TJ, Baum M  
Screening of inherited breast cancer with DNA markers (Letter)  
Lancet **341**: 1422 (1993)
- 238 Jones AL, Powles TJ  
Chemoprevention of breast cancer  
Review on Endocrine-Related Cancer **43**: 33-42 (1993)

- 239 Kanis J, McCloskey E, O'Rourke N, Khan S, Fern D, Eyres K, Sirtori P, Taube T, Powles T, Paterson A  
Clodronate in hypercalcaemia and osteolytic bone disease due to breast cancer.  
Saudi Medical Journal **14(2)**:93-97 (1993)
- 240 Powles TJ, Paterson A, Kanis J.  
Clodronate decreases skeletal morbidity in patients with bone metastases from breast cancer: A double blind randomised controlled trial.  
In: Metastatic Bone Disease. Eds Diel, Kaufmann, Bastert  
Publisher Springer-Verlag, Heidelberg. 1993, p 177-179
- 241 Smith IE, Powles TJ. MMM (Mitoxantrone, Methotrexate and Mitomycin C): An effective new regimen in the treatment of metastatic breast cancer.  
Oncology **50 (Suppl 1)** 9-15 (1993)
- 242 Murray PA, Gomm J, Ricketts D, Powles TJ, Coombes RC  
The effect of endocrine therapy on the levels of oestrogen and progesterone receptor and transforming growth factor beta-1 in metastatic human breast cancer: an immunocytochemical study  
Eur J Cancer **30(A) No 9**: 1218-1222 (1994)
- 243 Powles TJ, Jones AL, Ashley SE, O'Brien MER, Tidy VA, Treleavan J, Cosgrove D, Nash AG, Sacks N, Baum M, McKinna JA, Davey JB  
The Royal Marsden Hospital pilot tamoxifen chemoprevention trial  
Breast Cancer Research and Treatment **31**: 73-82 (1994)
- 244 Dowsett M, Smithers D, Moore JW, Trunet P, Coombes RC, Powles TJ, Rubens RD, Smith IE  
Endocrine changes with aromatase inhibitor fadrozole hydrochloride in breast cancer  
Eur J Cancer **30A(10)**: 1453-58 (1994)
- 245 Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, Campbell S.  
Effects of tamoxifen on the uterus and ovaries of women involved in a randomised breast cancer prevention trial. Lancet **343**: 1318-1321 (1994)
- 246 MacNeill FA, Jacobs S, Lonning PE, Powles TJ, Dowsett M.  
Combined treatment with 4-Hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression.  
Br J Cancer **69**: 1171-1175 (1994)
- 247 Powles TJ, Montes A, O'Brien M, Ashley SE, Nash AG, Sacks N, Ford HT, Fernando I, Cosgrove D.  
Mitoxantrone combination chemotherapy used with tamoxifen in the neoadjuvant therapy of breast cancer. In: Pharmanual: Mitoxantrone in the treatment of early breast cancer. Ed G Bonadonna.  
PharmaLibri, Chicago 41-49 (1994)

- 248 O'Brien MER, Casey S, Treleaven J, Powles TJ. Use of Erythropoietin in the management of the haemolytic uraemic syndrome induced by Mitomycin C/tamoxifen *European Journal of Cancer* **30A (6)**: 894-895 (1994) (Letter)
- 249 O'Brien MER, Nicolson M, Montes A, Tidy A, Ashley S, Powles TJ  
Phase 1 study of mitozantrone, methotrexate and mitomycin with granulocyte colony-stimulating factor (filgrastim) in patients with advanced breast cancer  
*British Journal of Cancer*, **70**: 980-983 (1994)
- 250 Powles TJ and Ashley S. Endometrial cancer during tamoxifen treatment. *Lancet* 343: 978, 1994 (Letter)
- 251 Fernando I, Titley JC, Powles TJ, Dowsett M, Trott PA, Ashley SE, Ford HT, Ormerod MG  
Measurement of S-phase fraction and ploidy in sequential fine-needle aspirates from primary human breast tumours treated with tamoxifen  
*British Journal of Cancer* 1994; **70**: 1211-16
- 252 Powles TJ, Hickish TF, Makris A, Ashley SE, O'Brien M, Tidy V, Casey S, Nash AG, Sacks N, Cosgrove D, MacVicar D, Fernando I, Ford HT  
A randomised trial of chemo-endocrine therapy started before (neoadjuvant) or after (adjuvant) surgery for treatment of primary breast cancer  
*Journal of Clinical Oncology*, **13**: 547-552, 1995
- 253 Martin EA, Rich KJ, White INH, Woods KL, Powles TJ, Smith LL  
32P-postlabelled DNA adducts in liver obtained from women treated with tamoxifen  
*Carcinogenesis* 16(7): 1651-54 (1995)
- 254 Makris A, Powles TJ, Dowsett M, Allred C. p53 protein overexpression and chemosensitivity in breast cancer (Letter). *Lancet* 1995; **345**: 1181-2
- 255 Powles TJ, Hickish T. Breast cancer response to hormone replacement therapy withdrawal (letter). *Lancet* 1995; **345**: 1442
- 256 Fernando IN, Powles TJ, Dowsett M, Ashley S, McRobert L, Titley J, Ormerod MG, Sacks N, Nicolson MC, Nash A, Ford HT, Allan SM, Trott PA. Determining factors which predict response to primary medical therapy in breast cancer using a single fine needle aspirate with immunocytochemical staining and flow cytometry. *Virchows Archiv* (1995); **426**: 155-161
- 257 Powles TJ & Hickish TH. Tamoxifen therapy and carcinogenic risk (Editorial). *Journal of the National Cancer Institute*, 1995; 87: 1343-45
- 258 Paterson AHG, Kanis JA, Powles TJ, McCloskey E, Hanson J, Ashley S. Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer. *Canadian Journal of Oncology* 1995; 5(1) (supplement): 54-57

- 259 O'Brien MER, Montes A, Powles TJ. Hormone replacement therapy as treatment of breast cancer - a phase II study of Org OD 14 (Tibolone) *British Journal of Cancer* **73**: 1086-1088 (1996)
- 260 Powles TJ, O'Brien MER  
The management of women with a high risk of breast cancer: The role of prophylactic tamoxifen. In: *Genetic Predisposition to Cancer*. Eds: Eeles, Ponder, Easton, Horwich. Chapman and Hall, London. pp 267-271,1996.
- 261 Powles TJ, Hickish T, Kanis JA, Tidy VA, Ashley S. The effect of tamoxifen on bone mineral density measured by dual energy xray absorptiometry in healthy pre and postmenopausal women. *J Clin Oncol* 1996; **14**(1): 78-84
- 262 Bonnefoi HR, Smith IE, Dowsett M, Trunet PF, Huston SJ, da Luz RJ, Rubens RD, Coombes RC, Powles TJ. Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer. *British Journal of Cancer* 1996; **73**: 539-542
- 263 Kanis JA, Powles TJ, Paterson AHG, McCloskey EV, Ashley S. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. *Bone* 1996; **19**: 663-667
- 264 Bonnefoi H, Smith IE, O'Brien MER, Seymour MT, Powles TJ, Allum WH, Ebbs S, Baum M. Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional E-carbo-F): a very active and well tolerated outpatient regimen. *British Journal of Cancer* 1996; **73**: 391-396
- 265 Chang J, Powles TJ, Ashley SE, Gregory RK, Tidy VA, Singh R. The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy women participating in a randomised, controlled tamoxifen prevention study. *Annals of Oncology* 1996; **7**: 671-675
- 266 Vinnicombe SJ, MacVicar AD, Guy RL, Sloane JP, Powles TJ, Knee G, Husband JE. Primary breast cancer: Mammographic changes after neoadjuvant chemotherapy, with pathologic correlation. *Radiology* 1996; **198**: 333-340
- 267 Gregory RK, Chang J, Singh R, Powles TJ. Clubbing, Arthralgia and Haemoptysis in a patient with metastatic carcinoma of the breast. *Annals of Oncology* 1996; **7**: 756-757
- 268 Dowsett M, Makris, Ellis P, Johnston SRD, Salter J, Detre S, Humphries S, Saccani-Jotti G, Powles TJ, Smith IE. Oncogene products and other diagnostic markers in human breast cancer patients, in Castagnetta L, Nenci I, Bradlow HL (eds). *Basis for cancer management*. *Annals of the New York Academy of Sciences*, vol 784. New York Academy of Sciences (New York) 1996, pp 403-411.

- 269 Thirlaway K, Fallowfield L, Nunnerley H, Powles T. Anxiety in women 'at risk' of developing breast cancer. (Short communication). *British Journal of Cancer* (1996) 73: 1422-24
- 270 Fernando IN, Ford HT, Powles TJ, Ashley S, Glees JP, Torr M, Grafton D, Harmer CL. Factors affecting acute skin toxicity in patients having breast irradiation after conservative surgery: a prospective study of treatment practice at the Royal Marsden Hospital. *Clinical Oncology* 1996; 8: 226-233
- 271 Fernando IN, Powles TJ, Ashley S, Grafton D, Harmer CL, Ford HT. An acute toxicity study on the effects of synchronous chemotherapy and radiotherapy in early stage breast cancer after conservative surgery. *Clinical Oncology* 1996; 8: 234-238
- 272 Powles TJ. Efficacy of tamoxifen as treatment of breast cancer. *Seminars in Oncology* 1997; 24(1) Suppl 1: 48-54
- 273 Iveson TJ, Powles TJ. Chemotherapy and Endocrine Manipulation. In: *Clinical Endocrine Oncology*. Eds: Sheaves R, Jenkins P, Wass J. Blackwell Science, Oxford. 1997 pp 58-63
- 274 Powles TJ, Chang J. Chemoprevention of breast cancer: why is tamoxifen not the answer? *Endocrine-Related Cancer* 1997; 4: 135-139
- 275 Chang J, Powles TJ. Breast Cancer Chemoprevention. In: Bonadonna G, Hortobagyi GN, Gianni AM (eds). *Textbook of Breast Cancer - A Clinical Guide to Therapy*. Martin Dunitz Ltd, London. 1997 pp 335-340.
- 276 Makris A, Powles TJ, Dowsett M, Osborne CK, Trott PA, Fernando IN, Ashley S, Ormerod MG, Titley JC, Gregory RK and Allred DC. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. *Clinical Cancer Research* 1997; 3: 593-600.
- 277 Makris A, Allred DC, Powles TJ, Dowsett M, Fernando IN, Trott PA, Ashley SE, Ormerod MG, Titley JC, Osborne CK. Cytological evaluation of biological prognostic markers from primary breast carcinomas. *Breast Cancer Research and Treatment* 1997; 44: 65-74.
- 278 Powles TJ. Chemoprevention of breast cancer using tamoxifen. *Endocrine-Related Cancer: Special Beatson Centenary Issue* 1997; 4(3): 255-260
- 279 Gregory RK, Chang J, Powles TJ, Treleavan J. Leukaemic infiltration or primary carcinoma of the breast in a patient with acute myeloid leukaemia? *The Breast* 1997; 6: 303-305
- 280 Powles TJ. Adjuvant therapy for early breast cancer: a time to refine (Editorial). *JNCI* 1997; 89 (22): 1652-54.

- 281 Powles TJ. Evolving clinical strategies: innovative approaches to the use of mitoxantrone. *European Journal of Cancer Care* 1997; **6**, Suppl 1: 1-3
- 282 Gregory RK, Powles TJ, Chang JC, Ashley S. A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast. *European Journal of Cancer* 1997; **33 (13)**: 2194-2197
- 283 J Chang, TJ Powles, SE Ashley, T Iveson, RK Gregory, M Dowsett. Variation in endometrial thickening in women with amenorrhoea on tamoxifen. *Breast Cancer Research and Treatment* 1998; **48**: 81-85
- 284 Makris A, Powles TJ, Allred DC, Ashley S, Ormerod MG, Titley JC, Dowsett M. Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response. *Breast Cancer Research and Treatment* 1998; **48**: 11-20
- 285 P Osin, T Crook, T Powles, B Gusterson. Hormone status of *in situ* cancer in BRCA1/BRCA2 mutation carriers (Letter). *Lancet* 1998; **351**: 1487
- 286 TJ Powles, E McCloskey, AHG Paterson, S Ashley, VA Tidy, A Nevantaus, K Rosenqvist, J Kanis. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. *J Nat Cancer Inst* 1998; **90**: 704-708
- 287 TJ Powles. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement - Editorial *Eur J Cancer* 1998; 34(5): 603-605
- 288 Powles TJ, Bourne T, Athanasiou S, Chang J, Grübock K, Ashley S, Oakes L, Tidy A, Davey J, Viggers J, Humphries S, Collins W. The effects of norethisterone on endometrial abnormalities identified by transvaginal ultrasound screening of healthy postmenopausal women on tamoxifen or placebo. *British Journal of Cancer* 1998; 78(2): 272-275
- 289 Powles TJ, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, Tidy A, Viggers J, Davey J. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. *Lancet* 1998; 352: 98-101
- 290 TJ Powles. Status of anti-oestrogen breast cancer prevention trials. *Oncology* 1998; 12: 28-31
- 291 TJ Powles. Tamoxifen's oestrogen-like effects in a breast cancer chemoprevention trial. *Eur J Cancer* 1998 34: S17-S18
- 292 Makris A, Powles TJ, Ashley SE, Chang J, Hickish T, Tidy VA, Nash AG,

Ford HT. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. *Annals of Oncology* 1998; 9: 1179-1184

- 293 Makris A, Powles TJ, Allred DC, Ashley SE, Trott PA, Ormerod MG, Titley JC, Dowsett M. Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: A pilot study. *Breast Cancer Research and Treatment* 1999; 53: 51-59
- 294 Trevor Powles. A review of results from the NSABP and Royal Marsden chemoprevention trials. *Primary Care and Cancer* 1999, 19 (3): 21-25

- 295 M Dowsett, C Archer, L Assersohn, RK Gregory, P Ellis, J Salter, J Chang, P Mainwaring, I Boedinghaus, S Johnston, TJ Powles, IE Smith. Clinical studies of apoptosis and proliferation in breast cancer. *Endocrine-Related Cancer* 1999; 6: 25-28
- 296 TJ Powles. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study (Letter). *JNCI* 1999; 91: 730.
- 297 L Assersohn, TJ Powles. Breast cancer chemoprevention trials using tamoxifen. *Oncology in Practice* 3/98 1998; 14-16
- 298 Leach MO, Verrill M, Glaholm J, Smith TA, Collins DJ, Payne GS, Sharp JC, Ronen SM, McCready VR, Powles TJ, Smith IE. Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized <sup>31</sup>P measurements of response to treatment. *NMR Biomed* 1998; 11: 314-340
- 299 L Assersohn & TJ Powles. Breast cancer prevention using tamoxifen. In: *Breast cancer: Sharing the decision*. A Maslin & TJ Powles (Eds) Oxford University Press, England, 1999; pp 165-177.
- 300 Cummings SR, Eckert S, Krueger K, Grady D, Powles TJ, Cauley, JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC. The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial. *JAMA* 1999; 281: 2189-2197
- 301 Makris A, Powles TJ, Kakolyris S, Dowsett M, Ashley SE, Harris AL. Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in operable breast cancer. *Cancer* 1999; 85: 1996-2000
- 302 TJ Powles. Breast cancer prevention. *Update* 1999; 59(4): 252
- 303 J Chang, TJ Powles, DC Allred, SE Ashley, GM Clark, A Makris, L Assersohn, RK Gregory, CK Osborne, M Dowsett. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. *J Clin Oncol* 1999; 17: 3058-3063
- 304 L Assersohn & T J Powles. Primary medical treatment - the results of the NSABP-B18 trial and the Royal Marsden Hospital trial. In: *Primary medical therapy for breast cancer: Clinical and Biological aspects*. European School of Oncology Scientific Update, volume 4. Eds: M Dowsett, A Howell. Pubs: Elsevier Science. 1999; pp 3-11.
- 305 TJ Powles. Breast cancer prevention – Commentary. *Breast Cancer Research* 2000; 2:10-12
- 306 L Assersohn, TJ Powles, AG Nash, AJ Neal, N Sacks, J Chang, U Querci della Rovere, N Naziri. Local relapse in primary breast cancer patients with unexcised positive surgical margins after lumpectomy, radiotherapy and chemoendocrine therapy. *Annals of Oncology* 1999; 10: 1451-1455

- 307 J Chang, TJ Powles, DC Allred, SE Ashley, A Makris, RK Gregory, CK Osborne, M Dowsett. Prediction of clinical outcome from primary tamoxifen of biologic markers in breast cancer patients. *Clinical Cancer Research* 2000; 6: 616-621
- 308 TJ Powles. Current controversies in cancer: Tamoxifen for breast cancer prevention *Eur J Cancer* 2000; 36: 142-150
- 309 R Saso, S Kulkarni, P Mitchell, J Treleaven, G Swansbury, J Mehta, R Powles, S Ashley, A Kuan, T Powles. Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. *British Journal of Cancer*, 2000; 83(1): 91-94
- 310 TJ Powles. Combined treatment with buserelin and tamoxifen in premenopausal 3 (0 metastatic breast cancer: a randomized study. (Letter). *JNCI* 2000; 92: 2040
- 311 K Gregory, TJ Powles, J Salter, JC Change, S Ashley, M Dowsett. Prognostic relevance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy. *Breast Cancer Research and Treatment* 2000; 59(2): 171-175
- 312 RA Eeles, TJ Powles. Chemoprevention options for BRCA1 and BRCA2 mutation carriers. *J Clin Oncol* 2000; 18(21 suppl): 93S-99S
- 313 Chang J, Ormerod M, Powles TJ, Allred DC, Ashley SE, Dowsett M. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. *Cancer* 2000; 89(11): 2145-2152
- 314 Cauley JA, Norton L, Lippman ME, Eckeert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4 year results from the MORE trial. Multiple outcomes of raloxifene evaluation. *Breast Cancer Research and Treatment* 2001; 65(2): 125-134.
- 315 LJ Fallowfield, A Fleissig, R Edwards, A West, TJ Powles, A Howell, J Cuzick. Tamoxifen for the prevention of breast cancer: Psychosocial impact on women participating in randomised controlled trials. *J Clin Oncol* 2001; 19: 1885-1892
- 316 PJ Ross, TJ Powles. Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials. *Clinical Breast Cancer* 2001; 2: 33-36
- 317 Powles TJ. The Royal Marsden Hospital (RMH) Trial – key points and remaining questions. *Ann N Y Acad Sci*. 2001 Dec;949:109-12.
- 318 Powles TJ. Breast Cancer Prevention. *The Oncologist* 2002; 7(1): 60-64.

- 319 Powles TJ. Use of selective anti-oestrogens for the chemoprevention of breast cancer. In: Miller/Ingle (Eds). Endocrine therapy of breast cancer. Marcel Dekker Inc. New York. 2002 pp 303-308
- 320 Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer  
Christos Sotiriou, Trevor J Powles, Mitch Dowsett, Amir A Jazaeri, Andrew L Feldman, Laura Assersohn, Chandramouli Gadisetti, Steven K Libutti, Edison T Liu  
*Breast Cancer Res* 2002, 4: R3
- 321 L Assersohn, L Gangi, Y Zhao, M Dowsett, R Simon, TJ Powles, ET Liu. The feasibility of using fine needle aspiration from primary breast cancers for cDNA microarray analyses. *Clinical Cancer Research* 2002; 8: 794-801
- 322 TJ Powles. Neoadjuvant chemotherapy for operable breast cancer – review article. *Oncology* 2002; 16 (7): 889-890
- 323 TJ Powles, S Paterson, JA Kanis, E McCloskey, S Ashley, A Tidy, K Rosenqvist, I Smith L Ottestad, S Legault, M Pajunen, A Nevantaus, E Männistö, A Suovuori, S Atula, J Nevalainen, L Pylkkänen. A randomised placebo controlled trial of clodronate in patients with primary operable breast cancer. *JCO* 2002; 20: 3219-3224.
- 324 Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle J, Edge S, Mamounas EP, Gralow J, Goldstein LJ, Pritchard K, Brawn S, Cobleigh MA, Langer AM, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: Status report 2002. *JCO* 2002; 20: 3317-3327.
- 325 IBIS Working Party & Principal Investigators. First results from the International Breast Cancer Intervention Trial (IBIS-1): a randomised prevention trial. *Lancet* 2002; 360:817-824
- 326 Assersohn, L, Powles, TJ, Dowsett, M. Endocrine therapy of breast cancer. In: Wass/Shalet (Eds). *Oxford Textbook of Endocrinology and Diabetes*. Pubs: Oxford University Press, London, 2002; pp 1501-1509.
- 327 Powles TJ. Anti-oestrogenic prevention of breast cancer – the make or break point. *Nature Reviews Cancer* 2002; 2: 787-794.
- 328 Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P. Overview of the main outcomes in the breast cancer prevention trials. *Lancet* 2003; 361: 296-300

- 329 TJ Powles. Anti-oestrogenic chemoprevention of breast cancer – the need to progress. *Euro J Cancer* 2003; 39: 572-579
- 330 Winer EP, Hudis C, Burstein HJ, Bryant J, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gelber R, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology Technology Assessment Working Group Update: Use of aromatase inhibitors in the adjuvant setting. *J Clin Oncology* 2003; 21:
- 331 Sari Atula, Trevor Powles, Alexander Paterson Eugene McCloskey, Jaakko Nevalainen and John Kanis. Extended Safety Profile of Oral Clodronate After Long-Term Use in Primary Breast Cancer Patients. *Drug Safety* 2003; 26 (9): 661-671
- 332 Trevor Powles Isoflavones commentary. *Breast Cancer Research* 2004 6(3) 140-142
- 333 S Martino, J A Cauley, E Barrett-Connor, T J Powles, J Mershon, D Disch, R Secrest, S R Cummings. Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene. *JNCI* 2004; 96(23) 1751-1961
- 334 Trevor J. Powles. Endocrine Prevention of Breast Cancer. *Euro J Cancer Supplement* 2004; 2(9): 15-16
- 335 Winer EP, Hudis C, Burstein HJ, Bryant J, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gelber R, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. *J Clin Oncol* 2005 23(3): 619-629
- 336 R Erkkola, L Mattila, T Powles, J Heikkinen, B Toivola, P Korhonen, M Mustonen. Bone mineral density and lipid changes during 5 years of follow up in a study of prevention of breast cancer with toremifene in healthy, high-risk pre- and postmenopausal women. *Breast Cancer Research and Development* 2005 – In Press.
- 337 Trevor J Powles. Practical considerations in bone metastases in breast cancer. *Business Briefing – Longterm Healthcare* 2005, pp 14-18